Loading page

WholenessCommunity

Shop Learn Community Resources

Find a Provider Sell on WholenessLog in

Preparing your space

WholenessCommunity

A dedicated home where people navigating acute and chronic medical conditions find community, independent providers, and genuine support throughout their journey.

Support hours: Mon–Fri, 9:00 AM – 5:00 PM EST

Join the Community

Explore

Shop
Learn
Community
Resources

Providers

Find a Provider
Sell on Wholeness
Provider Onboarding

Support

Returns & Refunds
About Us
Contact Us
Case Studies

Join our wellness community

Weekly inspiration, provider spotlights and healing resources.

© 2026 WCM LLC, d/b/a Wholeness Community Marketplace. All rights reserved.

Privacy Policy Member Terms Provider Terms Returns & Refunds

Conditions & Recovery · Cancer Health Science · October 24, 2026

Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer

Adding the androgen blocked abiraterone reduced the risk of death by 25%.

Originally published by Cancer Health Science. We curate and add context; they did the reporting.

Read the full story at Cancer Health Science ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor